1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-6 of 6 (Search time: 0.004 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2014Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancerJonker, D.; Karapetis, C.; Harbison, C.; O'Callaghan, C.; Tu, D.; Simes, R.; Malone, D.; Langer, C.; Tebbutt, N.; Price, T.; Shapiro, J.; Siu, L.; Wong, R.; Bjarnason, G.; Moore, M.; Zalcberg, J.; Khambata-Ford, S.
2014Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidinesRansom, D.; Wilson, K.; Fournier, M.; Simes, R.; Gebski, V.; Yip, D.; Tebbutt, N.; Karapetis, C.; Ferry, D.; Gordon, S.; Price, T.
2014The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX studyCarter, H.; Zannino, D.; John Simes, R.; Schofield, D.; Howard, K.; Zalcberg, J.; Price, T.; Tebbutt, N.
2014Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancerBruhn, M.; Townsend, A.; Khoon Lee, C.; Shivasami, A.; Price, T.; Wrin, J.; Arentz, G.; Tebbutt, N.; Hocking, C.; Cunningham, D.; Hardingham, J.
2014The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsSegelov, E.; Chan, D.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Pavlakis, N.

Discover